Stockscreener 앱 받기
6.80
1.95%
0.13
시장 영업 전:
6.84
0.04
+0.59%
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Suvretta, Averill disclose multi-million share holdings in Lexeo Therapeutics (NASDAQ: LXEO) - Stock Titan
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Layoff Watch: Is Lexeo Therapeutics Inc backed by strong institutional buying2026 Big Picture & Expert Curated Trade Setup Alerts - baoquankhu1.vn
CEO Change: Is Lexeo Therapeutics Inc attractive for institutional investors2026 Intraday Action & Accurate Intraday Trade Tips - baoquankhu1.vn
Insiders In Lexeo Therapeutics Left Out From 14% Price Rise After Disposing Stock - simplywall.st
Insider Sell: Richard Townsend Sells 55,000 Shares of Lexeo Ther - GuruFocus
Lexeo Therapeutics CEO Townsend sells $313k in shares By Investing.com - Investing.com Canada
Lexeo (LXEO) CEO sells 55,000 shares, keeps 340K including RSUs - Stock Titan
[144] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan
If You Invested $1,000 in Lexeo Therapeutics Inc (LXEO) - Stock Titan
Lexeo Therapeutics (LXEO) Price Target Increased by 19.77% to 21.29 - MSN
LXEO Technical Analysis & Stock Price Forecast - intellectia.ai
Published on: 2026-04-02 23:43:24 - baoquankhu1.vn
LXEO Earnings History & Surprises | EPS & Revenue Results | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Oppenheimer Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? - Yahoo Finance
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating - Investing.com
Lexeo Therapeutics 2025 Annual Report: Advancing Genetic Medicine for Cardiovascular Diseases - Minichart
Big Picture: Should I invest in Lexeo Therapeutics Inc before earnings2026 AllTime Highs & Verified High Yield Trade Plans - baoquankhu1.vn
Lexeo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances - TipRanks
Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results - MarketBeat
Lexeo Therapeutics | 10-K: Annual report - Moomoo
Gene therapy advances at Lexeo Therapeutics (NASDAQ: LXEO) target heart disease - Stock Titan
Lexeo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Runway into 2028 as Lexeo (NASDAQ: LXEO) pushes pivotal cardiac gene therapies - Stock Titan
Lexeo Therapeutics : Corporate Presentation March 2026 - marketscreener.com
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - ChartMill
US Market Wrap: Is Lexeo Therapeutics Inc on track to beat earnings2026 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Vanguard realignment leads to separate LXEO holdings reporting (LXEO) - Stock Titan
Aug Mood: Will Lexeo Therapeutics Inc outperform its industry peers2026 Action & Capital Efficient Trading Techniques - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - MSN
Wall Street Recap: Is Lexeo Therapeutics Inc. subject to activist investor interestTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Hedge Fund Moves: Does Lexeo Therapeutics Inc have declining or rising EPSMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-03-22 00:04:32 - baoquankhu1.vn
Oppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform Recommendation - msn.com
Is Lexeo Therapeutics Inc forming a bullish divergence2026 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
Lexeo Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - Stock Titan
Signal Recap: Can Lexeo Therapeutics Inc ride the EV waveMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday - MarketBeat
Rare disease spotlight: Friedreich ataxia moves beyond mitochondrial bandages - biocentury.com
LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
LXEO: Pivotal studies for FA and PKP2 advance with strong clinical data, robust manufacturing, and solid financials - TradingView — Track All Markets
Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4%What's Next? - MarketBeat
Sectors Review: Is Lexeo Therapeutics Inc. subject to activist investor interestWeekly Trade Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Lexeo Therapeutics Inc a cyclical or defensive stockMarket Volume Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Published on: 2026-03-07 09:09:20 - baoquankhu1.vn
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - The Manila Times
Genetic medicine firm Lexeo to stream Leerink conference chat - Stock Titan
Nasdaq Moves: Can Lexeo Therapeutics Inc ride the EV waveRate Cut & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference - MarketBeat
2.69%
0.25%
자본화:
|
볼륨(24시간):